Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Efficacy and Safety of Influenza Vaccine in Cancer Patients Receiving Immune Checkpoint Inhibitor

NCT03590808 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.

NCT NCT03590808
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03590808 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Efficacy and Safety of Influenza Vaccine in Cancer Patients Receiving Immune Checkpoint Inhibitor
Lead sponsor
Seoul National University Hospital
Phase
Not applicable
Overall status
Completed
Start date
September 1, 2018
Completion date
May 30, 2019
Enrollment
143 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

influenza, solid carcinoma